<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3980503</article-id><article-id pub-id-type="publisher-id">1745-6215-14-S1-O77</article-id><article-id pub-id-type="doi">10.1186/1745-6215-14-S1-O77</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Maishman</surname><given-names>Tom</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Stanton</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Davies</surname><given-names>Andy</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Barrans</surname><given-names>Sharon</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Worrillow</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Mamot</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Care</surname><given-names>Matt</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Immins</surname><given-names>Tikki</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Hamid</surname><given-names>Debbie</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>McMillan</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Fields</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Jack</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Johnson</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Southampton Clinical Trials Unit, Southampton, Hampshire, UK</aff><aff id="I2"><label>2</label>Cancer Research UK Centre, Southampton General Hospital, Southampton, Hampshire, UK</aff><aff id="I3"><label>3</label>Haematological Malignancy Diagnostic Service (HMDS), St. James's Institute of Oncology, Leeds, UK</aff><aff id="I4"><label>4</label>Centre for Oncology, Haematology and Transfusion Medicine, Kantonsspital Aarau, Tellstrasse, Switzerland</aff><aff id="I5"><label>5</label>Section of Experimental Haematology, Leeds Institute of Molecular Medicine, Leeds, UK</aff><aff id="I6"><label>6</label>Department of Haematology, Nottingham City Hospital, Nottingham, UK</aff><aff id="I7"><label>7</label>Department of Haematology, Guy's Hospital, London, UK</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2013</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">2nd Clinical Trials Methodology Conference: Methodology Matters</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by the 2nd Clinical Trials Methodology Conference.</named-content></supplement><fpage>O77</fpage><lpage>O77</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Maishman et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Maishman et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/14/S1/O77"/><conference><conf-date>18-19 November 2013</conf-date><conf-name>2nd Clinical Trials Methodology Conference: Methodology Matters</conf-name><conf-loc>Edinburgh, UK</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Retrospective molecular profiling of untreated Diffuse Large B-Cell Lymphoma (DLBCL) samples has recognised distinct sub-classifications of this disease, each with unique biological features and clinical outcomes.</p></sec><sec><title>Objectives</title><p>(i) To demonstrate superior clinical efficacy, of bortezomib in combination with rituximab and CHOP (RB-CHOP) versus R-CHOP for the treatment of previously untreated patients with DLBCL.</p><p>(ii) To assess whether the molecular phenotype determines benefit from the addition of bortezomib.</p></sec><sec sec-type="methods"><title>Methods</title><p>The trial uses an adaptive design and aims to recruit 940 patients across 100 sites in the UK and Switzerland (currently recruited 398 patients). After being profiled within real time (during cycle 1), ABC, GCB and unclassifiable molecular phenotype patients are randomised to receive RB-CHOP or R-CHOP with equal allocation. Two interim analyses will be carried out to stop the good prognosis GCB group early if required using a Case Morgan [<xref ref-type="bibr" rid="B1">1</xref>] analysis:</p><p>(i) The first will be a safety analysis performed after the first 55 GCB RB-CHOP patients have been followed for 6 months. If 6 month PFS&#x0003c;80%, the GCB group will close.</p><p>(ii) The second will be for futility in the GCB group and performed after the first 73 GCB RB-CHOP patients have been followed for 1 year. If 1 year PFS&#x0003c;85%, the GCB group will close.</p><p>If the GCB group closes the trial will then be modified to a randomised Phase II trial in ABC patients and sample size calculations will be revised.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Case</surname><given-names>LD</given-names></name><name><surname>Morgan</surname><given-names>TM</given-names></name><article-title>Design of Phase II cancer trials evaluating survival probabilities</article-title><source>BMC Medical Research Methodology</source><year>2003</year><volume>14</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-3-6</pub-id><pub-id pub-id-type="pmid">12697051</pub-id></mixed-citation></ref></ref-list></back></article>